Jacqueline M Bos1, Patricia M L A van den Bemt2, Wietske Kievit3, Johan L W Pot4, J Elsbeth Nagtegaal4, André Wieringa5, Monique M L van der Westerlaken4, Gert Jan van der Wilt3, Peter A G M de Smet6, Cornelis Kramers1,7. 1. Department of Clinical Pharmacy, Canisius Wilhelmina Hospital, Nijmegen, the Netherlands. 2. Department of Clinical Pharmacy, Erasmus University Medical Centre, Rotterdam, the Netherlands. 3. Department of Health Evidence, Radboud University Medical Centre, Nijmegen, the Netherlands. 4. Department of Clinical Pharmacy, Meander Medical Centre, Amersfoort, the Netherlands. 5. Department of Clinical Pharmacy, Isala Hospital, Zwolle, the Netherlands. 6. Department Scientific Institute for Quality of Healthcare, Radboud University Medical Centre, Nijmegen, the Netherlands. 7. Department of Clinical Pharmacology and Toxicology, Radboud University Medical Centre, Nijmegen, the Netherlands.
Abstract
AIM: The P-REVIEW study was a prospective, multicenter, open intervention study, designed to determine whether a multifaceted intervention of educating the prescriber combined with medication review and pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction in drug-related complications among surgical patients. METHODS: A total of 6780 admissions of 5940 patients to surgical, urological and orthopaedic wards during the usual care period and 6484 admissions of 5711 patients during the intervention period were included. An educational programme covering pain management, antithrombotics, fluid and electrolyte management, prescription in case of renal insufficiency and antibiotics was developed. National and local hospital guidelines were included. Hospital pharmacists performed medication safety consultations, combining medication review of high-risk patients and a visit to the physician on the ward. RESULTS: A significantly lower proportion of admissions with one or more clinically relevant, potentially preventable, drug-related problems (including death, temporary or sustained disability, increased length of hospital stay or readmission within 30 days) occurred in the intervention period (1.1% (73/6484) compared to the usual care period [1.6% (106/6780)] (P = 0.029). The relative risk (RR) was 0.72 (95% CI 0.53-0.97). Several types of drug-related problems occurred less frequently. Costs incurred as result of time spent on study-related activities were not different before and after the intervention. CONCLUSIONS: The P-REVIEW study shows that education and support of the prescribing physician with respect to high-risk patients in surgical departments leads to a significant, clinically relevant benefit for patients without generating additional costs.
AIM: The P-REVIEW study was a prospective, multicenter, open intervention study, designed to determine whether a multifaceted intervention of educating the prescriber combined with medication review and pharmaceutical visits to the ward by the hospital pharmacist could lead to a reduction in drug-related complications among surgical patients. METHODS: A total of 6780 admissions of 5940 patients to surgical, urological and orthopaedic wards during the usual care period and 6484 admissions of 5711 patients during the intervention period were included. An educational programme covering pain management, antithrombotics, fluid and electrolyte management, prescription in case of renal insufficiency and antibiotics was developed. National and local hospital guidelines were included. Hospital pharmacists performed medication safety consultations, combining medication review of high-risk patients and a visit to the physician on the ward. RESULTS: A significantly lower proportion of admissions with one or more clinically relevant, potentially preventable, drug-related problems (including death, temporary or sustained disability, increased length of hospital stay or readmission within 30 days) occurred in the intervention period (1.1% (73/6484) compared to the usual care period [1.6% (106/6780)] (P = 0.029). The relative risk (RR) was 0.72 (95% CI 0.53-0.97). Several types of drug-related problems occurred less frequently. Costs incurred as result of time spent on study-related activities were not different before and after the intervention. CONCLUSIONS: The P-REVIEW study shows that education and support of the prescribing physician with respect to high-risk patients in surgical departments leads to a significant, clinically relevant benefit for patients without generating additional costs.
Authors: Imaan Bayoumi; Mosab Al Balas; Steven M Handler; Lisa Dolovich; Brian Hutchison; Anne Holbrook Journal: Int J Med Inform Date: 2014-03-29 Impact factor: 4.046
Authors: Lilian H F Hoonhout; Martine C de Bruijne; Cordula Wagner; Henk Asscheman; Gerrit van der Wal; Maurits W van Tulder Journal: Drug Saf Date: 2010-10-01 Impact factor: 5.606
Authors: S M Huijts; C H van Werkhoven; W G Boersma; J Buijs; G Buunk; C J Compaijen; L J R van Elde; J E H Gisolf; R van der Kam; J A J W Kluytmans; B A F Kuipers; J J Mager; B Oppedijk; F Palmen; J M Prins; B van Reemst; M H Silbermann; F H van Tiel; E van der Wall; T S van der Werf; M J M Bonten Journal: Neth J Med Date: 2013-12 Impact factor: 1.422
Authors: Anita Krähenbühl-Melcher; Raymond Schlienger; Markus Lampert; Manuel Haschke; Jürgen Drewe; Stephan Krähenbühl Journal: Drug Saf Date: 2007 Impact factor: 5.606
Authors: Michael J Dooley; Karen M Allen; Christopher J Doecke; Kirsten J Galbraith; George R Taylor; Jennifer Bright; Dianne L Carey Journal: Br J Clin Pharmacol Date: 2004-04 Impact factor: 4.335
Authors: Joanna E Klopotowska; Peter C Wierenga; Clementine C M Stuijt; Lambertus Arisz; Marcel G W Dijkgraaf; Paul F M Kuks; Henk Asscheman; Sophia E de Rooij; Loraine Lie-A-Huen; Susanne M Smorenburg Journal: PLoS One Date: 2013-08-05 Impact factor: 3.240
Authors: Andrew D Baumgartner; Collin M Clark; Susan A LaValley; Scott V Monte; Robert G Wahler; Ranjit Singh Journal: J Clin Pharm Ther Date: 2019-12-24 Impact factor: 2.512
Authors: Jacqueline M Bos; Patricia M L A van den Bemt; Wietske Kievit; Johan L W Pot; J Elsbeth Nagtegaal; André Wieringa; Monique M L van der Westerlaken; Gert Jan van der Wilt; Peter A G M de Smet; Cornelis Kramers Journal: Br J Clin Pharmacol Date: 2016-11-10 Impact factor: 4.335
Authors: Jacqueline M Bos; Gerard A Kalkman; Hans Groenewoud; Patricia M L A van den Bemt; Peter A G M De Smet; J Elsbeth Nagtegaal; Andre Wieringa; Gert Jan van der Wilt; Cornelis Kramers Journal: PLoS One Date: 2018-08-23 Impact factor: 3.240
Authors: Lea Jung-Poppe; Hagen Fabian Nicolaus; Anna Roggenhofer; Anna Altenbuchner; Harald Dormann; Barbara Pfistermeister; Renke Maas Journal: J Clin Med Date: 2022-09-01 Impact factor: 4.964
Authors: Richard H Parrish; Heather Monk Bodenstab; Dustin Carneal; Ryan M Cassity; William E Dager; Sara J Hyland; Jenna K Lovely; Alyssa Pollock; Tracy M Sparkes; Siu-Fun Wong Journal: J Clin Med Date: 2022-09-24 Impact factor: 4.964
Authors: Jacqueline M Bos; Stephanie Natsch; Patricia M L A van den Bemt; Johan L W Pot; J Elsbeth Nagtegaal; Andre Wieringa; Gert Jan van der Wilt; Peter A G M De Smet; Cornelis Kramers Journal: Int J Clin Pharm Date: 2017-11-03
Authors: Rashudy F Mahomedradja; Kim C E Sigaloff; Jessica K Bekema; Marieke J H J Dekker; David J Brinkman; Marianne A Kuijvenhoven; Marlou L H van Beneden; Birgit I Lissenberg-Witte; Jelle Tichelaar; Michiel A van Agtmael Journal: Br J Clin Pharmacol Date: 2020-07-09 Impact factor: 3.716